Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source

Source document· April 13, 2026

Small Molecule Innovator API CDMO Market Outlook, 2026-2033 - Lonza Group, Novo Holdings (Catalent) and Thermo Fisher Scientific Lead the Growing Industry

View original at finance.yahoo.com

Small Molecule Innovator API CDMO Market Outlook, 2026-2033 - Lonza Group, Novo Holdings (Catalent) and Thermo Fisher Scientific Lead the Growing Industry Company Logo With a focus on specialty medicines, growth is driven by pharmaceutical needs for cost-effective, efficient production and regulatory compliance via CDM…

Opening lines of the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

Market expansion is fueled by a growing demand for small molecule drugs, an increase in outsourcing trends among pharmaceutical companies, and a surge in clinical trials
60% confidence
Small molecule applications constitute over half of specialty sales
60% confidence
Only 11% of APIs are based in the U.S., with most sourced internationally
60% confidence
By February 2024, the global tally of registered clinical trials on ClinicalTrials.gov reached 483,592, marking a significant rise from the over 365,000 reported in early 2021. Of these, 66,206 trials are actively recruiting
60% confidence
The global small molecule innovator API CDMO market is projected to expand significantly, with an estimated size of USD 26.66 billion in 2025, expected to reach USD 43.75 billion by 2033, growing at a CAGR of 6.55% from 2026 to 2033
60% confidence

Data points we hold from this source

U.S. Food and Drug Administration · drug approvals	46 novel_drugs
U.S. Food and Drug Administration · drug approvals	50 novel_drugs